Scientific Education Support
Multiple Myeloma Hub
The Multiple Myeloma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in multiple myeloma. Our aim is to enhance knowledge in multiple myeloma, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management. Hosted on Acast. See acast.com/privacy for more information.
Be sure to visit the podcast's website and support the creator: multiplemyelomahub.com
Author
Scientific Education Support
Category
Podcast website
Latest episode
Nov 17, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
With the unprecedented results seen with novel therapies, what is needed to overcome the poor prognosis of high-risk MM? 30.06.2021 5:09
During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Pieter Sonneveld, Erasmus MC, Rotterdam, NL. We asked, With the unprecedented results seen with novel therapies, what is needed to overcome the poor prognosis of high-risk multiple myeloma (MM)? In this podcast, Sonneveld discusses trial results presented during EHA2021 on the efficacy of novel treatments for patients with hi...
When BCMA-directed therapy is not an option, how should we treat late relapse? 24.05.2021 3:09
During the European School of Haematology (ESH) 3rd How to Diagnose and Treat Multiple Myeloma conference, the Multiple Myeloma Hub spoke to Xavier Leleu, Poitiers University Hospital, Poitiers, FR. We asked, When BCMA-directed therapy is not an option, how should we treat late relapse? Leleu discusses three alternatives to anti-B-cell maturation antigen (BCMA) directed therapies, including altern...
What do you need to remember when facing CAR T-cell toxicities? 12.04.2021 11:05
During the 3rd European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to Professor Philip McCarthy, Roswell Park Comprehensive Cancer Center, Buffalo, US. We asked, What do you need to remember when facing CAR T-cell toxicities? In this podcast, McCarthy discusses the two main chimeric antigen receptor (CAR) T-cell toxicities: cytokine release syndrome (CRS), and immune effector cell-associat...
What are the key additions to the new NCCN guidelines for multiple myeloma? 07.04.2021 14:03
During the National Comprehensive Cancer Network (NCCN) 2021 Annual Conference, the Multiple Myeloma Hub spoke to Natalie S. Callander, University of Wisconsin-Madison, Madison, US and Shaji K. Kumar, Mayo Clinic, Rochester, US. We asked, What are the key additions to the new NCCN guidelines for multiple myeloma? Callander and Kumar discuss the inclusion of new diagnostic tools, such as MRD testin...
If maintenance after induction reduces therapy options at relapse, is it still worth it? 01.04.2021 9:49
During the 2nd European Myeloma Network Meeting, the Multiple Myeloma Hub spoke to Professor Graham Jackson, Newcastle University, Newcastle upon Tyne, UK, and Professor Philippe Moreau, CHU de Nantes, Nantes, FR. We asked, If maintenance after induction reduces therapy options at relapse, is it still worth it? Currently, the only approved maintenance therapy for multiple myeloma is lenalidomide....
New findings on the role of the immune microenvironment presented at ASH 2020 16.02.2021 26:37
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Elisabet E. Manasanch, MD Anderson Cancer Center, Houston, US, and Taxiarchis Kourelis, Mayo Clinic, Rochester, US. They discuss new findings regarding the role of the immune microenvironment presented at ASH 2020 In this podcast, Manasanch and Kourelis describe two studies on immu...
ASH 2020 discussion: Looking for the best partner for lenalidomide maintenance after auto-SCT 09.02.2021 17:26
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Francesca Gay (University of Turin, Turin, IT) and Jonathan L. Kaufman (Emory University, Atlanta, US) about the best partner for lenalidomide maintenance after autologous stem cell transplantation. In this podcast, Kaufman and Gay discuss data from studies evaluating multiple myel...
Should we still use high-dose melphalan in the era of novel agents? 09.02.2021 9:54
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Nikhil C. Munshi, Dana-Farber Cancer Institute, Boston, US. We asked, Should we still use high-dose melphalan in the era of novel agents? In this podcast, Munshi discusses the role of high-dose chemotherapy combined with stem cell transplantation in the era of novel agents....
What are the unmet needs in AL amyloidosis in Europe? 01.02.2021 11:44
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Efstathios Kastritis, National and Kapodistrian University of Athens, Athens, GR. We asked, What are the unmet needs in AL amyloidosis in Europe? AL amyloidosis is a rare disease caused by the accumulation of amyloid fibers in tissues and organs. In this podcast, Kastritis out...
ASH 2020 discussion: The role of upfront transplant consolidation in the era of novel agents 27.01.2021 13:50
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Marc Braunstein, NYU Langone Health, New York, US, and Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR, about the role of upfront transplant consolidation in the era of novel agents. Long-term follow-up data about upfront autologous hematopoietic stem cell t...
Can single cell sequencing help to better define and monitor MM? 17.12.2020 17:51
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Maximilian Merz, Heidelberg University Hospital, Heidelberg, DE, and Nizar Bahlis, University of Calgary, Calgary, CA. We asked, Can single cell sequencing help to better define and monitor multiple myeloma? Merz highlights the importance of defining what you want to study, the mye...
My experience with novel immunotherapies 11.11.2020 11:48
During the European School of Haematology (ESH) 5th Translational Research E-Conference on Multiple Myeloma, the Multiple Myeloma Hub was pleased to speak to Hermann Einsele, University of Würzburg, Würzburg, DE, about novel immunotherapies. Bispecific antibodies and chimeric antigen receptor (CAR) T cells represent a novel interesting therapeutic option for patients with multiple myeloma. In this...
How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease 08.07.2020 24:34
During the American Association of Cancer Research (AACR) Virtual Annual Meeting I, the MM Hub was pleased to speak to Christine Spencer, Parker Institute for Cancer Immunotherapy, San-Francisco, US and Diwakar Davar, University of Pennsylvania Medical Center, Pittsburgh, US. We asked: how can we use the microbiome to improve cancer immunotherapy and alleviate side effects such as graft- versus -h...
Melphalan flufenamide (melflufen) + novel agents for RRMM 08.07.2020 18:21
During COMy 2020, Multiple Myeloma Hub Steering Committee Member Paul Richardson, Dana-Farber Cancer Institute, Boston, US, spoke to the Multiple Myeloma Hub about advances in the novel, peptide-conjugated alkylator, melphalan flufenamide (melflufen). Melflufen has been successful in overcoming resistance to standard chemotherapeutics as well as novel agents, such as proteasome inhibitors and immu...
Isatuximab plus KRd for high-risk NDMM 24.06.2020 7:40
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Katja Weisel, University Cancer Center Hamburg, Hamburg, DE. In this podcast she discusses the quadruplet combination of isatuximab with carfilzomib, lenalidomide and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. In this podcast, Katja Weisel des...
Novel approaches in multiple myeloma: what is unique about CELMoDs? 24.06.2020 13:21
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Paul Richardson, Dana-Farber Cancer Institute, Boston, US. In this podcast he discusses cereblon E3 ligase modulators (CELMoDs) as a novel approach in the treatment of relapsed/refractory multiple myeloma. Paul Richardson describes how preclinical data have shown CC-92480 to h...
Hot topics in MM: quadruplets and anti-BCMA therapy 24.06.2020 6:16
During the 25th Congress of the European Hematology Association (EHA), the Multiple Myeloma Hub was pleased to speak to Saad Usmani, Levine Cancer Institute, Atrium Health, Charlotte, US. In this podcast he discusses data from three clinical trials, which address the use of quadruplet treatments and anti-BCMA therapy for multiple myeloma. He describes the progression free survival, overall surviva...
Genomics of high-risk myeloma 23.06.2020 15:18
During COMy 2020, Nikhil Munshi, Dana-Farber Cancer Institute, Boston, US, spoke to the Multiple Myeloma Hub about genomics of high-risk MM. Here, Nikhil Munshi highlights the positive shift in survival outcomes of patients with high-risk MM in recent years, owing to emerging treatments and diagnostic techniques. Three major points are discussed: 1. Who is high risk? 2. What are the characteristic...
The association between the diversity of the oral microbiome and PFS 22.06.2020 7:23
During the 25th Congress of the European Hematology Association (EHA), the Multiple Myeloma Hub spoke to Steering Committee Member Heinz Ludwig, Wilhelminen Cancer Research Institute, Vienna, AT. This podcast outlines a study that aimed to determine the impact of the oral microbiome in patients uniformly treated with ixazomib + thalidomide + dexamethasone combination therapy for the treatment of r...
Novel approaches in multiple myeloma: BFCR4350A 18.06.2020 6:53
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myleoma Hub was pleased to speak to Adam Cohen, University of Pennsylvania, Philadelphia, US. In this podcast, he discussed the use of BFCR4350A, a novel bispecific FcRH5:CD3 T-cell engaging antibody, in patients with relapsed/refractory multiple myeloma. Adam Cohen provides us with insights from pre-clinical data...
Updates from the KarMMa trial 18.06.2020 7:13
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Nikhil Munshi, Dana-Farber Cancer Institute, Boston, US. In this podcast, he discusses the recent updates from the KarMMa phase II trial (NCT03361748). in patients with relapsed/refractory multiple myeloma. Nikhil Munshi describes the mechanism of action of the idecabtagene vicl...
Update from CARTITUDE-1 | What's new since ASH? 08.06.2020 5:56
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Jesus Berdeja, Sarah Cannon Research Institute, Nashville, US. In this podcast, he discusses the latest updates from the CARTITUDE-1. This was a phase I/IIb study of JNJ-4528, a B cell maturation antigen (BCMA)-directed chimeric antigen receptor T (CAR T)-cell therapy in patient...
Novel approaches in multiple myeloma: TAK-079 04.06.2020 5:46
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Amrita Krishnan, City of Hope, Duarte, US. In this podcast, she discussed the phase I data of TAK-079, a novel anti-CD38 monoclonal antibody, in a heavily pre-treated population of patients with multiple myeloma. She begins be describing the uniqueness of TAK-079 over other appr...
Should we use KRd or VRd for patients with NDMM? 04.06.2020 7:12
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Shaji Kumar, Mayo Clinic, Rochester, US. We asked: Should we use carfilzomib, lenalidomide, and dexamethasone (KRd) or bortezomib, lenalidomide, and dexamethasone (VRd) for patients with newly diagnosed multiple myeloma (NDMM)? In this podcast he describes the results of the E...
What is the optimal treatment for bone lesions, including patients with renal insufficiency? 03.06.2020 7:21
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Elizabeth O'Donnell, Massachusetts General Hospital, Boston, US. We asked: what is the optimal treatment for bone lesions, including patients with renal insufficiency? In this podcast, Elizabeth O'Donnell discusses how bone-directed therapy is an important component of multipl...
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.